

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

GLAXOSMITHKLINE PLC
Form 6-K
April 11, 2008

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending April 11, 2008

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F
or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No

--

Notification of Transactions of Directors, Persons Discharging Managerial
Responsibility or Connected Persons

I give below details of changes in the interests of Directors, Persons
Discharging Managerial Responsibility or Connected Persons in the Ordinary
shares of GlaxoSmithKline plc in respect of the under-mentioned persons arising
from the purchase of Ordinary shares at a price of GBP11.06 per Ordinary share
on 10 April 2008 through the Company's ShareReward Plan ("the Plan") which the
under-mentioned persons entered on 5 October 2001:

Mr J S Heslop	Acquisition of 23 Ordinary shares under the Dividend Reinvestment element of the Plan
---------------	--

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Mr E J Gray	Acquisition of 23 Ordinary shares under the Dividend Reinvestment element of the Plan
Mr D Learmouth	Acquisition of 23 Ordinary shares under the Dividend Reinvestment element of the Plan
Dr D Pulman	Acquisition of 11 Ordinary shares under the Dividend Reinvestment element of the Plan
Mr C Viehbacher	Acquisition of 4 Ordinary shares under the Dividend Reinvestment element of the Plan
Mr A P Witty	Acquisition of 23 Ordinary shares under the Dividend Reinvestment element of the Plan

The Company and the above-mentioned persons were advised of this information on 11 April 2008.

This notification relates to a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1) (a).

S M Bicknell
Company Secretary

11 April 2008

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: April 11, 2008

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc